Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study to Evaluate the Efficacy and Safety of GB226 for the Treatment of Chinese Population With Relapsed and Refractory Peripheral T Cell Lymphoma (PTCL)

NCT03502629 is registered in ClinicalTrials.gov with Genor Biopharma Co., Ltd. as lead sponsor.

NCT NCT03502629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03502629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study to Evaluate the Efficacy and Safety of GB226 for the Treatment of Chinese Population With Relapsed and Refractory Peripheral T Cell Lymphoma (PTCL)
Lead sponsor
Genor Biopharma Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
July 2, 2018
Completion date
December 30, 2022
Enrollment
86 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t cell lymphoma